The year 2020 was a year when the global pharmaceutical industry was profoundly affected by the epidemic. It was also a year when China’s API industry withstood the test of fluctuations in the international market. According to the preliminary statistics of China Chamber of Commerce for Medical Insurance, in 2020, China’s API exports reached us $35.7 billion, another record high, with a year-on-year growth of about 6%.
Despite its significant contributions to cancer research, the use of NMU also raises health and safety concerns. As an alkylating agent, NMU is recognized for its mutagenic and carcinogenic potential. It underscores the importance of handling such chemicals with care in laboratory settings to mitigate risk to researchers and the environment. Proper safety protocols must be observed, emphasizing the necessity of responsible research practices in the field of cancer biology.